Your browser doesn't support javascript.
loading
Mitochondrial haplogroups and cognitive progression in Parkinson's disease.
Liu, Ganqiang; Ni, Chunming; Zhan, Jiamin; Li, Weimin; Luo, Junfeng; Liao, Zhixiang; Locascio, Joseph J; Xian, Wenbiao; Chen, Ling; Pei, Zhong; Corvol, Jean-Christophe; Maple-Grødem, Jodi; Campbell, Meghan C; Elbaz, Alexis; Lesage, Suzanne; Brice, Alexis; Hung, Albert Y; Schwarzschild, Michael A; Hayes, Michael T; Wills, Anne-Marie; Ravina, Bernard; Shoulson, Ira; Taba, Pille; Kõks, Sulev; Beach, Thomas G; Cormier-Dequaire, Florence; Alves, Guido; Tysnes, Ole-Bjørn; Perlmutter, Joel S; Heutink, Peter; van Hilten, Jacobus J; Barker, Roger A; Williams-Gray, Caroline H; Scherzer, Clemens R.
Affiliation
  • Liu G; Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.
  • Ni C; Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.
  • Zhan J; Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.
  • Li W; Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.
  • Luo J; Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.
  • Liao Z; APDA Center for Advanced Parkinson Research, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Locascio JJ; Neurogenomics Lab, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Xian W; APDA Center for Advanced Parkinson Research, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Chen L; Neurogenomics Lab, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Pei Z; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Corvol JC; Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
  • Maple-Grødem J; Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
  • Campbell MC; Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
  • Elbaz A; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Assistance Publique Hôpitaux de Paris, Département de Neurologie et de Génétique, Hôpital Pitié-Salpêtrière, F-75013 Paris,
  • Lesage S; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, 4068 Stavanger, Norway.
  • Brice A; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway.
  • Hung AY; Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Schwarzschild MA; Paris-Saclay University, UVSQ, Inserm, Gustave Roussy, 'Exposome and Heredity' Team, CESP, F94805 Villejuif, France.
  • Hayes MT; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Assistance Publique Hôpitaux de Paris, Département de Neurologie et de Génétique, Hôpital Pitié-Salpêtrière, F-75013 Paris,
  • Wills AM; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Assistance Publique Hôpitaux de Paris, Département de Neurologie et de Génétique, Hôpital Pitié-Salpêtrière, F-75013 Paris,
  • Ravina B; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Shoulson I; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Taba P; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Kõks S; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Beach TG; Praxis Precision Medicines, Cambridge, MA 02142, USA.
  • Cormier-Dequaire F; Department of Neurology, Center for Health and Technology, University of Rochester, Rochester, NY 14642, USA.
  • Alves G; Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu 50406, Estonia.
  • Tysnes OB; Neurology Clinic, Tartu University Hospital, Tartu 50406, Estonia.
  • Perlmutter JS; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Perth, WA 6150, Australia.
  • Heutink P; Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
  • van Hilten JJ; Banner Sun Health Research Institute, Sun City, AZ 85351, USA.
  • Barker RA; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Assistance Publique Hôpitaux de Paris, Département de Neurologie et de Génétique, Hôpital Pitié-Salpêtrière, F-75013 Paris,
  • Williams-Gray CH; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, 4068 Stavanger, Norway.
  • Scherzer CR; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway.
Brain ; 146(1): 42-49, 2023 01 05.
Article in En | MEDLINE | ID: mdl-36343661
ABSTRACT
Mitochondria are a culprit in the onset of Parkinson's disease, but their role during disease progression is unclear. Here we used Cox proportional hazards models to exam the effect of variation in the mitochondrial genome on longitudinal cognitive and motor progression over time in 4064 patients with Parkinson's disease. Mitochondrial macro-haplogroup was associated with reduced risk of cognitive disease progression in the discovery and replication population. In the combined analysis, patients with the super macro-haplogroup J, T, U# had a 41% lower risk of cognitive progression with P = 2.42 × 10-6 compared to those with macro-haplogroup H. Exploratory analysis indicated that the common mitochondrial DNA variant, m.2706A>G, was associated with slower cognitive decline with a hazard ratio of 0.68 (95% confidence interval 0.56-0.81) and P = 2.46 × 10-5. Mitochondrial haplogroups were not appreciably linked to motor progression. This initial genetic survival study of the mitochondrial genome suggests that mitochondrial haplogroups may be associated with the pace of cognitive progression in Parkinson's disease over time.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease Limits: Humans Language: En Journal: Brain Year: 2023 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease Limits: Humans Language: En Journal: Brain Year: 2023 Type: Article Affiliation country: China